Articles on Nucleoside Analogue-Sparing Regimen

A Nucleoside Analogue-sparing Strategy for Treatment of Chronic HIV - 3/16/05


Articles on Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Treatment Interruption as a Viable Option in Patients with Lowest CD4 Cell Count >250 Cells - 10/21/05

New Nucleoside Analog Reverset (D-d4FC) Shows Promise in Phase II Study of Treatment-experienced Patients - 7/27/05

Report on the XIV International HIV Drug Resistance Workshop: Parts 1-3 - 7/06/05

Greater and More Rapid Depletion of Mitochondrial DNA in Blood of Patients Treated with Dual vs. Single NRTIs - 4/11/05

Meta-analysis Finds Boosted-PIs (BPI) and NNRTI-containing Regimens Provide Superior Virologic Suppression Compared to Protease Inhibitor and NRTI-containing regimens, and BPI-containing regimens offer the Greatest Increase in CD4 Cells - 3/04/05

HIV Therapy Has Saved More Than 2 Million Years of Life in US - 3/02/05

Tolerance of a Short Course of Nevirapine, Associated with 2 Nucleoside Analogues, in Postexposure Prophylaxis of HIV - 1/10/05

Similar Adherence Rates Favor Different Virologic Outcomes for Patients Treated with Non Nucleoside Analogues or Protease Inhibitors - 1/10/05

NRTIs May Show Continued Anti-HIV Activity Despite Long Durations of Partially Suppressive Therapy and the Presence of Resistant HIV - 12/10/04

Predictors of Selection of K65R Mutation: Tenofovir Use and Lack of Thymidine Analogue Mutations - 10/18/04

The Triple Nucleoside Combination of Abacavir, Zidovudine, and Lamivudine Proves "Virologically Inferior" to a Non Nucleoside Efavirenz- based Regimen in HIV Treatment-naïve Patients - 04/30/04

Treatment of HIV/AIDS in Patients Failing Their First HAART Regimen - 04/28/04

Abacavir Versus Zidovudine Combined with Lamivudine and Efavirenz for Treatment-naïve Patients - 10/06/04

The Role of HBV Genotypes in the Outcome of Hepatitis B Virus Infection - 09/27/04

Experimental NRTI MIV-310 Efficiently Reduces HIV Viral Load in Patients Failing Multiple Drug Therapy: Results from a 4-week Phase II Study - 09/20/04

Pharmacokinetic Properties of Nucleoside/Nucleotide Reverse Transcriptase Inhibitors - 09/13/04

The Ideal Nucleoside/Nucleotide Backbone - 09/01/04

Patients Who Use Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Before HAART Experience an Increased Rate of Virus Rebound  - 08/16/04

Acetyl-L-carnitine Reverses NRTI-related Nerve Degeneration - 8/11/04